Exscientia CEO Professor Andrew Hopkins
Dundee life sciences firm Exscientia has access to almost £400 million after its latest fundraising round.
The Dundee University spin-out company uses artificial intelligence (AI) to design drugs.
Its latest funding round raised $225m (£162m) with an additional $300m (£216m) available from SoftBank at Exscientia’s discretion.
What will the money be used for?
Chief executive Andrew Hopkins said the investment would be used to expand the firm’s drug pipeline and discovery capabilities.
He said: “All of our investors share Exscientia’s vision to discover better drugs, faster, through AI and automation.
Chief executive and founder of Dundee-based Exscientia, Professor Andrew Hopkins.